[Harbin Sanlian Pharmaceutical Co., Ltd. 2025 H1 Earnings Forecast](index=1&type=section&id=%E5%93%88%E5%B0%94%E6%BB%A8%E4%B8%89%E8%81%94%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) [H1 2025 Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a significant year-over-year decline and a net loss for the first half of 2025 H1 2025 Performance Forecast | Item | Current Period (H1 2025) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: RMB 98.00 million - 80.00 million | Profit: RMB 26.27 million | | YoY Change | Decline: 473.03% - 404.52% | - | | **Net Profit Excl. Non-recurring Items** | Loss: RMB 95.00 million - 77.00 million | Profit: RMB 21.13 million | | YoY Change | Decline: 549.50% - 464.33% | - | | **Basic Earnings Per Share (EPS)** | Loss: RMB 0.30/share - 0.24/share | Profit: RMB 0.08/share | [Communication with the Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company clarifies that the financial data in this earnings forecast has not been audited by an accounting firm - The financial data in this earnings forecast **has not been audited** by an accounting firm[4](index=4&type=chunk) [Explanation of Performance Fluctuation](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The shift from profit to loss is driven by lower product prices, increased depreciation, and inventory provisions [Decline in Sales Prices](index=1&type=section&id=3.1%20%E9%94%80%E5%94%AE%E4%BB%B7%E6%A0%BC%E4%B8%8B%E9%99%8D) Product selling prices fell due to national procurement policies and market competition, reducing revenue and gross profit - Product sales prices declined due to national drug procurement policies and intensified market competition[6](index=6&type=chunk) H1 2025 Forecasted Impact of Price Decline | Metric | H1 2025 Forecast | YoY Change | | :--- | :--- | :--- | | Revenue | RMB 413 million | Decrease of RMB 110 million | | Gross Profit | - | Decrease of RMB 107 million | [Operating Costs and Period Expenses](index=2&type=section&id=3.2%20%E8%90%A5%E4%B8%9A%E6%88%90%E6%9C%AC%E5%8F%8A%E6%9C%9F%E9%97%B4%E8%B4%B9%E7%94%A8) Depreciation and financial expenses increased, while selling and R&D expenses decreased - Operating costs remained relatively stable, but **depreciation expenses increased significantly by over RMB 14 million** YoY due to the capitalization of construction projects[7](index=7&type=chunk) - Overall period expenses decreased, with a combined **reduction of over RMB 27 million in selling and R&D expenses**, though financial expenses rose by over RMB 12 million[7](index=7&type=chunk) [Provision for Inventory Impairment](index=2&type=section&id=3.3%20%E8%AE%A1%E6%8F%90%E5%AD%98%E8%B4%A7%E5%87%8F%E5%80%BC%E5%87%86%E5%A4%87) An inventory impairment provision of approximately RMB 11 million is expected for H1 2025 due to lower product selling prices - An **inventory impairment provision of approximately RMB 11 million** is expected for H1 2025 due to declining sales prices[7](index=7&type=chunk) [Other Relevant Information](index=2&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company states this forecast is a preliminary estimate and advises investors to refer to the final H1 2025 report - This earnings forecast is a preliminary estimate by the finance department; **final data will be in the official H1 report**[8](index=8&type=chunk)

哈三联（002900）公告，2025年1月1日至2025年6月30日，预计归属于上市公司股东的净利润亏损9800 万元-8000万元，同比下降473.03%-404.52%；扣除非经常性损益后的净利润亏损9500万元–7700万元， 同比下降549.50%-464.33%；基本每股收益亏损0.3元/股–0.24元/股。公司2025年半年度收入预计4.13亿 元，毛利下降1.07亿元。 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-038 哈尔滨三联药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案或修改议案的情况；本次股东大会上无新提议 案提交表决； 2、本次股东大会不涉及变更前次股东大会决议的情况； 3、本次股东大会因涉及审议影响中小投资者利益的重大事项，公司将对中小 投资者表决情况进行单独计票。中小投资者是指以下股东以外的其他股东： （1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东。 一、会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 7 月 11 日（周五）16:00； （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 7 月 11 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 7 月 11 日 9:15-15:00 期间任意时间。 ...

北京市中伦律师事务所（以下简称"本所"）作为哈尔滨三联药业股份有限 公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2025 年第一次临时股东大会（以下简称"本次股东大会"）。本所律师根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）》《上市公司股东会规则》等相关法律、法规、规范性 文件及《哈尔滨三联药业股份有限公司章程》（以下简称"《公司章程》"）的 规定，对本次股东大会进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 法律意见书 北京市中伦律师事务所 关于哈尔滨三联药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：哈尔滨三联药业股份有限公司 即其已提供了本所律师认为 ...

Market Overview - The Shanghai Composite Index rose by 0.70% on July 8, with 29 out of the 31 sectors in the Shenwan classification experiencing gains, led by the communication and power equipment sectors, which increased by 2.89% and 2.30% respectively [1] - The pharmaceutical and biological industry saw a modest increase of 0.31% [1] - The sectors that declined included public utilities and banking, with decreases of 0.37% and 0.24% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets was 15.45 billion yuan, with 14 sectors experiencing net inflows [1] - The electronics sector had the highest net inflow, totaling 7.437 billion yuan, and it rose by 2.27% [1] - The power equipment sector followed with a net inflow of 3.678 billion yuan and a daily increase of 2.30% [1] - Conversely, 17 sectors experienced net outflows, with public utilities leading at a net outflow of 2.297 billion yuan, followed by the pharmaceutical and biological sector with a net outflow of 2.285 billion yuan [1] Pharmaceutical and Biological Sector Performance - Within the pharmaceutical and biological sector, 474 stocks were tracked, with 337 stocks rising and 123 stocks falling [2] - The top gainers included Zhaoyan New Drug, which saw a net inflow of 263 million yuan and a price increase of 8.27%, followed by Ha Sanlian and Mindray Medical with net inflows of 232 million yuan and 139 million yuan respectively [2] - The sector also had 10 stocks with net outflows exceeding 100 million yuan, with Changshan Pharmaceutical leading at a net outflow of 783 million yuan, followed by Yong'an Pharmaceutical and Hanyu Pharmaceutical with outflows of 236 million yuan and 208 million yuan respectively [4] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Zhaoyan New Drug: +8.27%, turnover rate 9.51%, net inflow 262.56 million yuan - Ha Sanlian: +10.00%, turnover rate 15.14%, net inflow 232.27 million yuan - Mindray Medical: +0.43%, turnover rate 0.44%, net inflow 138.84 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Changshan Pharmaceutical: -12.80%, turnover rate 8.90%, net outflow -783.11 million yuan - Yong'an Pharmaceutical: -5.88%, turnover rate 20.93%, net outflow -236.84 million yuan - Hanyu Pharmaceutical: -2.33%, turnover rate 20.52%, net outflow -207.84 million yuan [4]

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with PCB, CRO, and consumer electronics outsourcing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. PCB Sector - PCB concept stocks continued to strengthen, with International Composite Materials and Yidong Electronics hitting the 20% daily limit up. Jin'an Guoji achieved a four-day consecutive rise, while Honghe Technology had four limit-up days in six days [8][9]. Pharmaceutical Sector - The pharmaceutical sector was notably strong, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Lianhuan Pharmaceutical achieved a consecutive limit-up, while companies like Weixin Kang, Hasan Lian, and Xiaofang Pharmaceutical also hit the limit-up. Toxin Pharmaceutical and Ruizhi Pharmaceutical saw increases exceeding 10% [4][5][6]. Notable Stock Movements - Fujilai (301258) surged to a limit-up of 20.01%, reaching a price of 39.28 CNY per share shortly after opening. Other notable stocks included Tuoxin Pharmaceutical and Ruizhi Pharmaceutical, which rose by 13.27% and 12.88%, respectively [5][6]. Regulatory Issues - Ruiskanda faced a trading halt due to a 9.95% drop, attributed to regulatory issues involving its chairman and director, who are under criminal coercive measures for alleged violations related to information disclosure. The company had previously faced administrative penalties from the CSRC [11][13].

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with circuit board, CRO, and consumer electronics manufacturing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. Pharmaceutical Sector - The pharmaceutical sector experienced a strong opening, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Notable stocks included Lianhuan Pharmaceutical, which achieved a two-day limit up, and several others like Weixin Kang and Ha Sanlian hitting the daily limit [7][8]. - Fujilai (301258) surged to a limit up of 20% to reach a price of 39.28 CNY per share shortly after the market opened [8][9]. PCB Sector - PCB (Printed Circuit Board) stocks continued to strengthen, with companies like International Composite Materials and Yidong Electronics hitting the daily limit. Jin'an Guoji achieved a four-day limit up, while Honghe Technology recorded four limit ups in six days [12][13]. - The demand for high-end PCBs is rapidly increasing due to AI computing needs, leading to a significant supply-demand gap in AI PCBs this year. ASIC chip growth is expected to be the main driver of incremental demand for high-end PCBs by 2026 [14][15]. Company-Specific News - Ruisi Kanda faced a trading halt with a limit down of 9.95% due to allegations of information disclosure violations, leading to criminal measures against its executives [17][20]. - ST Huaming also experienced a limit down of 20.03% following administrative penalties for false disclosures in its financial reports [20].

Core Viewpoint - The Heilongjiang Provincial Drug Administration announced the results of the GMP compliance inspections for 16 pharmaceutical companies, confirming their adherence to the 2010 revised Good Manufacturing Practice standards [3]. Group 1: Compliance Inspection Results - Heilongjiang Sanlian Pharmaceutical Co., Ltd. was inspected for its small-volume injection production line, specifically for anti-tumor drugs, and found compliant [3]. - Harbin Pharmaceutical Group's second factory was inspected for its granule and oral liquid production lines, confirming compliance [3]. - Heilongjiang Huabei Pharmaceutical Co., Ltd. was inspected for its solid dosage forms and traditional Chinese medicine extraction processes, and was found compliant [3]. Group 2: Inspection Details - The inspections were conducted between April and May 2025, with specific dates for each company listed [3]. - The inspection covered various production lines, including small-volume injections, oral liquids, and traditional Chinese medicine extracts [3]. - The results indicate a focus on ensuring quality and compliance within the pharmaceutical manufacturing sector in Heilongjiang Province [3].

证券代码：002900 证券简称：哈三联 公告编号：2025-037 哈尔滨三联药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 二、担保进展情况 1、近日，公司与中信银行股份有限公司（哈尔滨分行）（以下简称"中信银 行"） 签订了编号为"【2025 信银哈最高额保证合同（线下版）（3.0 版，2023 年） 字第 105401 号】"的《最高额保证合同》，同意为"兰西制药"与中信银行在一 定期限内连续发生的多笔债务的履行提供最高额保证担保，所担保债权之最高额 限度为债权本金人民币壹仟万元整和相应的利息、罚息、复利、违约金、损害赔 偿金、迟延履行期间的债务利息、迟延履行金及为实现债权、担保权利等所发生 的一切费用（包括但不限于诉讼费、仲裁费、律师费、差旅费、评估费、过户费、 保全费、公告费、公证认证费、翻译费、执行费、保全保险费等）和其他所有应 付的费用之和。 2、近日，公司与兴业银行股份有限公司（哈尔滨分行）（以下简称"兴业银 行"） 签订了编号为"202556216 保证 2002 号"的《最高额保证合同 ...

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. plans to expand its business scope to include the production of plastic packaging containers for food, following the approval of the board of directors and pending shareholder approval [1][5]. Business Scope Change - The company's previous business scope included various pharmaceutical and healthcare-related activities such as drug production, wholesale, retail, and medical device manufacturing [2][4]. - The new business scope will add "production of plastic packaging containers for food" to its existing operations, which encompass drug production, cosmetics production, food production, and medical device manufacturing [2][4]. Company Charter Revision - The company has revised its charter to reflect the changes in its business scope, ensuring that the new activities are officially documented [3][5]. - The charter revision maintains all other provisions unchanged, and the board has requested authorization from the shareholders to handle subsequent business registration procedures [5].